ES2857848T3 - Compuestos tricíclicos como agentes antineoplásicos - Google Patents

Compuestos tricíclicos como agentes antineoplásicos Download PDF

Info

Publication number
ES2857848T3
ES2857848T3 ES18192207T ES18192207T ES2857848T3 ES 2857848 T3 ES2857848 T3 ES 2857848T3 ES 18192207 T ES18192207 T ES 18192207T ES 18192207 T ES18192207 T ES 18192207T ES 2857848 T3 ES2857848 T3 ES 2857848T3
Authority
ES
Spain
Prior art keywords
optionally substituted
methyl
alkyl
compound
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18192207T
Other languages
English (en)
Spanish (es)
Inventor
Derek J Norris
George V Delucca
Ashvinikumar V Gavai
Claude A Quesnelle
Patrice Gill
Daniel O'malley
Wayne Vaccaro
Francis Y Lee
Mikkel V Debenedetto
Andrew P Degnan
Haiquan Fang
Matthew D Hill
Hong Huang
William D Schmitz
Starrett, Jr
Wen-Ching Han
John S Tokarski
Sunil Kumar Mandal
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2857848T3 publication Critical patent/ES2857848T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
ES18192207T 2013-12-24 2014-12-23 Compuestos tricíclicos como agentes antineoplásicos Active ES2857848T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361920500P 2013-12-24 2013-12-24

Publications (1)

Publication Number Publication Date
ES2857848T3 true ES2857848T3 (es) 2021-09-29

Family

ID=52293305

Family Applications (2)

Application Number Title Priority Date Filing Date
ES14824743T Active ES2698998T3 (es) 2013-12-24 2014-12-23 Compuestos tricíclicos como agentes antineoplásicos
ES18192207T Active ES2857848T3 (es) 2013-12-24 2014-12-23 Compuestos tricíclicos como agentes antineoplásicos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES14824743T Active ES2698998T3 (es) 2013-12-24 2014-12-23 Compuestos tricíclicos como agentes antineoplásicos

Country Status (34)

Country Link
US (1) US20160318928A1 (OSRAM)
EP (2) EP3087071B1 (OSRAM)
JP (2) JP6466456B2 (OSRAM)
KR (1) KR102457145B1 (OSRAM)
CN (2) CN108558871B (OSRAM)
AR (2) AR099379A1 (OSRAM)
AU (1) AU2014369982B2 (OSRAM)
BR (1) BR112016013744B1 (OSRAM)
CA (1) CA2934953C (OSRAM)
CL (1) CL2016001629A1 (OSRAM)
CY (2) CY1121076T1 (OSRAM)
DK (2) DK3466949T3 (OSRAM)
EA (2) EA201990240A1 (OSRAM)
ES (2) ES2698998T3 (OSRAM)
HR (2) HRP20181849T1 (OSRAM)
HU (2) HUE054183T2 (OSRAM)
IL (1) IL246359B (OSRAM)
LT (2) LT3087071T (OSRAM)
MA (1) MA39211B1 (OSRAM)
MX (1) MX369491B (OSRAM)
MY (1) MY176489A (OSRAM)
NZ (1) NZ722326A (OSRAM)
PE (1) PE20160844A1 (OSRAM)
PH (1) PH12016500953A1 (OSRAM)
PL (2) PL3466949T3 (OSRAM)
PT (2) PT3466949T (OSRAM)
RS (2) RS61479B1 (OSRAM)
SG (1) SG11201605097SA (OSRAM)
SI (2) SI3466949T1 (OSRAM)
SM (2) SMT201800643T1 (OSRAM)
TN (1) TN2016000238A1 (OSRAM)
TW (2) TWI736517B (OSRAM)
UY (1) UY35916A (OSRAM)
WO (1) WO2015100282A1 (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014134267A1 (en) 2013-02-27 2014-09-04 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
WO2015070020A2 (en) 2013-11-08 2015-05-14 Dana-Farber Cancer Institute, Inc. Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
PL3466949T3 (pl) * 2013-12-24 2021-05-31 Bristol-Myers Squibb Company Związek tricykliczny jako środki przeciwrakowe
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
US9580430B2 (en) * 2014-02-28 2017-02-28 The Regents Of The University Of Michigan 9H-pyrimido[4,5-B]indoles and related analogs as BET bromodomain inhibitors
WO2016183115A1 (en) * 2015-05-12 2016-11-17 Bristol-Myers Squibb Company 5h-pyrido[3,2-b]indole compounds as anticancer agents
US9725449B2 (en) 2015-05-12 2017-08-08 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
JP7032311B2 (ja) 2015-07-16 2022-03-08 バイオエクセル セラピューティクス，インコーポレイテッド 免疫調節を使用してがんを処置するための新規手法
EP3355922A2 (en) * 2015-10-02 2018-08-08 Dana Farber Cancer Institute, Inc. Combination therapy of bromodomain inhibitors and checkpoint blockade
KR102238012B1 (ko) * 2016-01-20 2021-04-09 닝보 웬다 파르마 테크놀로지 엘티디 브로모도메인 억제제인 카르볼린 유도체
WO2017124934A1 (zh) * 2016-01-20 2017-07-27 宁波文达医药科技有限公司 作为布罗莫区结构域抑制剂的含膦咔啉衍生物
EP3412669A4 (en) * 2016-02-05 2019-09-04 Chia Tai Tianqing Pharmaceutical Group Co.,Ltd TRICYCLIC COMPOUND FOR PROTEIN INHIBITOR CONTAINING BROMODOMAINE AND PREPARATION, PHARMACEUTICAL COMPOSITION AND USE THEREOF
IL297201A (en) 2016-03-01 2022-12-01 Corcept Therapeutics Inc Use of glucocorticoid receptor modulators to increase the activity of checkpoint inhibitors
US10150754B2 (en) * 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
US20190284192A1 (en) 2016-11-10 2019-09-19 Luoxin Pharmaceutical (Shanghai) Co., Ltd. Nitrogenous macrocyclic compound, preparation method therefor, pharmaceutical composition and application thereof
CN109824693B (zh) * 2017-04-18 2020-12-08 四川大学 Brd4抑制剂及其在肿瘤治疗药物中的应用
WO2019080941A1 (en) * 2017-10-27 2019-05-02 Jacobio-Beta Pharmaceuticals Co., Ltd. NEW TRICYCLIC COMPOUNDS
KR102600391B1 (ko) 2018-06-25 2023-11-10 자코바이오 파마슈티칼스 컴퍼니 리미티드 삼중고리형 화합물
CN108840868B (zh) * 2018-08-01 2019-10-18 上海山的实业有限公司 具有抗肿瘤活性的吲哚并吡啶酮类化合物的制备方法及应用
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
WO2020200284A1 (zh) * 2019-04-04 2020-10-08 上海华汇拓医药科技有限公司 三环类化合物制备方法及其在医药领域的应用
CN110003204B (zh) * 2019-04-30 2020-08-11 上海勋和医药科技有限公司 一种bet蛋白抑制剂、其制备方法及用途
US10947253B2 (en) 2019-08-05 2021-03-16 Ankh Life Sciences Limited Fused polycyclic dimers
JP7642552B2 (ja) 2019-09-30 2025-03-10 協和キリン株式会社 Ｂｅｔ分解剤
US12129265B2 (en) 2020-07-21 2024-10-29 Ankh Life Sciences Limited Therapeutic agents and uses thereof
AU2022211285A1 (en) * 2021-01-22 2023-08-17 Jingrui Biopharma Co., Ltd. Tricyclic compounds as anticancer agents
CA3206708A1 (en) * 2021-02-25 2022-09-01 Ida ARONCHIK Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
WO2022234337A2 (en) * 2021-05-06 2022-11-10 Raziel Therapeutics Ltd. Crystalline carbazole derivative
WO2024099441A1 (en) * 2022-11-11 2024-05-16 Jingrui Biopharma (Shandong) Co., Ltd. Bromodomain and extra-terminal (bet) protein degrader

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0623125A1 (en) * 1992-01-15 1994-11-09 E.I. Du Pont De Nemours And Company Bridged heterocyclic fungicides
JP2007509045A (ja) 2003-10-18 2007-04-12 バイエル・ヘルスケア・アクチェンゲゼルシャフト 尿失禁および関連疾患の処置用のｇａｂａアゴニストとしての５−置換２−（フェニルメチル）チオ−４−フェニル−４ｈ−１，２，４−トリアゾール誘導体および関連化合物
EP1686949A2 (en) * 2003-11-24 2006-08-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
DK1866339T3 (da) 2005-03-25 2013-09-02 Gitr Inc GTR-bindende molekyler og anvendelser heraf
GB0507298D0 (en) 2005-04-11 2005-05-18 Novartis Ag Organic compounds
WO2006122150A1 (en) 2005-05-10 2006-11-16 Incyte Corporation Modulators of indoleamine 2,3-dioxygenase and methods of using the same
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
JP5294874B2 (ja) 2005-12-20 2013-09-18 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロ環
US7696166B2 (en) 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
CL2007002650A1 (es) 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
JP5319532B2 (ja) 2006-09-19 2013-10-16 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CA2932121A1 (en) 2007-11-30 2009-06-11 Newlink Genetics Corporation Ido inhibitors
FR2927330B1 (fr) 2008-02-07 2010-02-19 Sanofi Aventis Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antagonistes des recepteurs a l'urotensine ii
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
US8815840B2 (en) * 2008-12-19 2014-08-26 Bristol-Myers Squibb Company Carbazole and carboline kinase inhibitors
US8709424B2 (en) 2009-09-03 2014-04-29 Merck Sharp & Dohme Corp. Anti-GITR antibodies
ES2601226T3 (es) 2009-10-28 2017-02-14 Newlink Genetics Corporation Derivados de imidazol como inhibidores de IDO
RS58693B1 (sr) 2009-12-10 2019-06-28 Hoffmann La Roche Antitela koja poželjno vezuju ekstracelularni domen 4 humanog csf1r, i njihova primena
TW201141872A (en) 2010-02-26 2011-12-01 Boehringer Ingelheim Int Cycloalkyl containing thienopyrimidines for pharmaceutical compositions
PH12018501083A1 (en) 2010-03-04 2019-02-18 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
BR112012020372A8 (pt) 2010-03-05 2018-01-02 Hoffmann La Roche anticorpo que se liga ao csf-1r humano, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira e método para a produção de um anticorpo recombinante
CA2789071C (en) 2010-03-05 2018-03-27 F. Hoffmann-La Roche Ag Antibodies against human csf-1r and uses thereof
TWI503323B (zh) * 2010-03-29 2015-10-11 Oncotherapy Science Inc 三環化合物以及含此化合物之ｐｂｋ抑制劑
KR20200044999A (ko) 2010-05-04 2020-04-29 파이브 프라임 테라퓨틱스, 인크. Ｃｓｆ1ｒ에 결합하는 항체들
EP2582698B1 (en) 2010-06-16 2016-09-14 Vitae Pharmaceuticals, Inc. Substituted 5-,6- and 7-membered heterocycles, medicaments containing such compounds, and their use
PH12020550156A1 (en) 2010-09-09 2024-01-15 Pfizer 4-1bb binding molecules
KR20140099556A (ko) * 2010-12-16 2014-08-12 에프. 호프만-라 로슈 아게 트라이사이클릭 pi3k 억제제 화합물 및 이의 사용 방법
US8580399B2 (en) 2011-04-08 2013-11-12 Universal Display Corporation Substituted oligoazacarbazoles for light emitting diodes
NO2694640T3 (OSRAM) 2011-04-15 2018-03-17
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
US9991447B2 (en) * 2011-09-28 2018-06-05 Idemitsu Korea Co., Ltd. Material for organic electroluminescent element, and organic electroluminescent element produced using same
RS61033B1 (sr) 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
US10023643B2 (en) 2011-12-15 2018-07-17 Hoffmann-La Roche Inc. Antibodies against human CSF-1R and uses thereof
BR112014018961A8 (pt) 2012-02-06 2017-07-11 Genentech Inc Anticorpo isolado, anticorpo biespecífico, fragmento, ácido nucleico isolado, vetor, célula hospedeira, método de produção de anticorpos, composição farmacêutica, uso do anticorpo, método de tratamento, método de inibição e artigo industrializado
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
BR112014028013A2 (pt) 2012-05-11 2018-02-27 Five Prime Therapeutics Inc métodos para tratar uma condição associada com artrite reumatoide, artrite reumatoide, lesões de pele, nefrite lúpica, lúpus, uma condição inflamatória, distúrbio de cd16+, método para reduzir o número de monócitos cd16+, métodos para desacelerar a progressão de uma condição renal,de formação de panos e de perda óssea
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
UA115576C2 (uk) * 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт Похідні бензимідазолу як антагоністи ер4
WO2014134267A1 (en) * 2013-02-27 2014-09-04 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
US9492460B2 (en) 2013-02-27 2016-11-15 Bristol-Myers Squibb Company Carbazole compounds useful as bromodomain inhibitors
WO2014164596A1 (en) * 2013-03-11 2014-10-09 The Regents Of The University Of Michigan Bet bromodomain inhibitors and therapeutic methods using the same
PL3466949T3 (pl) * 2013-12-24 2021-05-31 Bristol-Myers Squibb Company Związek tricykliczny jako środki przeciwrakowe

Also Published As

Publication number Publication date
TW202028203A (zh) 2020-08-01
HRP20210212T1 (hr) 2021-07-09
AU2014369982B2 (en) 2019-04-18
CA2934953A1 (en) 2015-07-02
BR112016013744B1 (pt) 2022-08-30
JP6675501B2 (ja) 2020-04-01
NZ722326A (en) 2019-09-27
EP3087071A1 (en) 2016-11-02
EA201990240A1 (ru) 2019-06-28
LT3087071T (lt) 2018-11-12
MA39211A1 (fr) 2018-08-31
HRP20181849T1 (hr) 2018-12-28
EP3087071B1 (en) 2018-09-05
PT3466949T (pt) 2021-02-25
IL246359B (en) 2020-04-30
IL246359A0 (en) 2016-08-31
CN108558871A (zh) 2018-09-21
SI3466949T1 (sl) 2021-03-31
PT3087071T (pt) 2018-11-29
JP6466456B2 (ja) 2019-02-06
CY1121076T1 (el) 2019-12-11
CA2934953C (en) 2022-09-20
ES2698998T3 (es) 2019-02-06
AR099379A1 (es) 2016-07-20
AU2014369982A1 (en) 2016-08-04
PL3087071T3 (pl) 2019-03-29
WO2015100282A1 (en) 2015-07-02
TWI736517B (zh) 2021-08-21
DK3466949T3 (da) 2021-03-15
DK3087071T3 (da) 2019-01-02
EP3466949A1 (en) 2019-04-10
US20160318928A1 (en) 2016-11-03
AR123996A2 (es) 2023-02-01
MA39211B1 (fr) 2019-01-31
EA201691070A1 (ru) 2016-11-30
MX2016007928A (es) 2016-08-03
SI3087071T1 (sl) 2018-11-30
EA032469B1 (ru) 2019-05-31
SG11201605097SA (en) 2016-07-28
KR102457145B1 (ko) 2022-10-19
TWI726544B (zh) 2021-05-01
SMT201800643T1 (it) 2019-01-11
TN2016000238A1 (en) 2017-10-06
BR112016013744A2 (OSRAM) 2017-10-03
LT3466949T (lt) 2021-03-25
PL3466949T3 (pl) 2021-05-31
MY176489A (en) 2020-08-12
RS61479B1 (sr) 2021-03-31
RS58014B1 (sr) 2019-02-28
CN108558871B (zh) 2022-02-18
UY35916A (es) 2015-06-30
JP2017505762A (ja) 2017-02-23
PH12016500953A1 (en) 2016-06-27
JP2019070014A (ja) 2019-05-09
KR20160095168A (ko) 2016-08-10
HRP20210212T8 (hr) 2021-08-20
HUE054183T2 (hu) 2021-08-30
TW201609725A (zh) 2016-03-16
CL2016001629A1 (es) 2017-02-17
CN106029663A (zh) 2016-10-12
MX369491B (es) 2019-11-11
SMT202100165T1 (it) 2021-05-07
PE20160844A1 (es) 2016-09-03
HUE041719T2 (hu) 2019-05-28
CN106029663B (zh) 2018-06-01
EP3466949B1 (en) 2020-12-23
CY1124061T1 (el) 2022-05-27

Similar Documents

Publication Publication Date Title
ES2857848T3 (es) Compuestos tricíclicos como agentes antineoplásicos
US10112941B2 (en) Tricyclic compounds as anticancer agents
JP6395731B2 (ja) ブロモドメイン阻害剤として有用なカルバゾール化合物
US12037323B2 (en) Uracil derivatives as Mer-AXL inhibitors
ES2815683T3 (es) Compuestos tricíclicos como agentes antineoplásicos
ES2770349T3 (es) Compuestos de 5H-pirido[3,2-b]indol como agentes antineoplásicos
US10292985B2 (en) TGF beta receptor antagonists
EP3341372A1 (en) Tgf beta receptor antagonists
US10399987B2 (en) TGF beta receptor antagonists
US10961239B2 (en) TGF beta receptor antagonists